Related Experiment Video

Updated: May 20, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Anti-inflammatory effects of interleukin-19 in vascular disease

Ross N England1, Michael V Autieri

  • 1Department of Physiology, Independence Blue Cross Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA.

International Journal of Inflammation
|July 31, 2012
PubMed

Insights

Vascular diseases, driven by inflammation, remain a major health concern. This study explores the role of inflammatory cytokines and introduces Interleukin-19 (IL-19) as a potential therapeutic target for vascular inflammatory disorders.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Molecular Medicine

Background:

  • Vascular diseases, including atherosclerosis, are a leading cause of mortality globally.
  • Inflammation and cytokine dysregulation are key drivers of vascular pathology.
  • Comorbidities like obesity and diabetes exacerbate vascular disease burden.

Purpose of the Study:

  • To examine the role of inflammatory cytokines and T helper cell (Th1/Th2) balance in vascular inflammation.
  • To investigate Interleukin-19 (IL-19), a Th2 cytokine, as a potential mediator of vascular inflammatory disorders.
  • To explore IL-19 as a novel therapeutic target for vascular inflammatory diseases.

Main Methods:

  • Review of existing literature on inflammatory cytokines and vascular inflammation.
  • Analysis of the role of T helper cell (Th1/Th2) polarity in atherosclerosis.
  • Examination of the function and potential therapeutic applications of Interleukin-19 (IL-19).

Main Results:

  • Inflammatory cytokines and Th1/Th2 imbalance are central to vascular inflammation, particularly in atherosclerosis.
  • Interleukin-19 (IL-19) is identified as a previously unrecognized mediator in vascular inflammatory disorders.
  • IL-19 shows potential as a therapeutic agent for combating vascular inflammation.

Conclusions:

  • Targeting inflammatory cytokines and modulating T helper cell responses are crucial for managing vascular diseases.
  • Interleukin-19 (IL-19) represents a promising new avenue for therapeutic intervention in vascular inflammatory conditions.
  • Further research into IL-19's mechanisms could lead to novel treatments for atherosclerosis and related diseases.

More Related Videos

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...